← Product Code [MID](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID) · K993085 # AUTOSTAT II ANTI-CARDIOLIPIN SCREEN ELISA (K993085) _Cogent Diagnotics , Ltd. · MID · Feb 1, 2000 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID/K993085 ## Device Facts - **Applicant:** Cogent Diagnotics , Ltd. - **Product Code:** [MID](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID.md) - **Decision Date:** Feb 1, 2000 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5660 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Intended Use Enzyme linked immunosorbent assay method for the detection of IgG, IgM and IgA autoantibodies to cardiolipin in human serum. Uses: The results of the anti-cardiolipin assay can be used as an aid in the diagnosis of autoimmune diseases associated with elevated levels of anti-cardiolipin antibodies including anti-phospholipid syndrome. Levels of these autoantibodies are one indicator in a multi-factorial diagnostic regime. The assay may be used on the Hycor Hy•Tec Automated EIA instrument. For in vitro diagnostic use only. ## Device Story Autostat™ II ACA Screen ELISA is an in vitro diagnostic assay for detecting IgG, IgM, and IgA autoantibodies to cardiolipin in human serum. The device utilizes an enzyme-linked immunosorbent assay (ELISA) method. It is designed for use on the Hycor Hy•Tec Automated EIA instrument. Clinicians use the assay results as one indicator within a multi-factorial diagnostic regime to aid in the diagnosis of autoimmune diseases, specifically anti-phospholipid syndrome. The device provides laboratory-based quantitative or qualitative antibody detection to support clinical decision-making regarding autoimmune pathology. ## Clinical Evidence No clinical data provided in the document; substantial equivalence is based on the 510(k) regulatory review process. ## Technological Characteristics Enzyme-linked immunosorbent assay (ELISA) for detection of IgG, IgM, and IgA autoantibodies. Designed for use on the Hycor Hy•Tec Automated EIA instrument. In vitro diagnostic device. ## Regulatory Identification A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies). ## Reference Devices - Hycor Hy•Tec Automated EIA instrument ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines above two wavy lines. ## 1 2000 FEB Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Cogent Diagnostics LTD c/o Mr. Randy Wilson Hycor Biomedical Inc. 7272 Chapman Avenue Garden Grove, California 92841 Re: K993085 Trade Name: Autostat™II ACA Screen ELISA Regulatory Class: II Product Code: MID Dated: November 19, 1999 Received: November 26, 1999 Dear Mr. Wilson: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {1}------------------------------------------------ Page 2 This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Butman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ Page__________________________________________________________________________________________________________________________________________________________________________ 510(k) Number (if known): K993085 Device Name: Jutostag ACA SCREEN ELISA ## Indications for Use. Enzyme linked immunosorbent assay method for the detection of IgG, IgM and IgA autoantibodies to cardiolipin in human serum. Uses: The results of the anti-cardiolipin assay can be used as an aid in the diagnosis of autoimmune diseases associated with elevated levels of anti-cardiolipin antibodies including anti-phospholipid syndrome. Levels of these autoantibodies are one indicator in a multi-factorial diagnostic regime. The assay may be used on the Hycor Hy•Tec Automated EIA instrument. For in vitro diagnostic use only. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Stutis E. Madani (Division Sign-Off) Division of Clinical Laboratory Devices K993085 510(k) Number Prescription Use Y (Per 21 CFR 801.109) OR - Over-The-Counter Use_ (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID/K993085](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MID/K993085) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com